Acta Pharmaceutica Sinica B publishes a special factor on “Research on emerging COVID-19 (objective, mechanism and therapeutics)”, edited by Hai-Bin Luo, Faculty of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China; Shilin Chen, Institute of Chinese Medical Matter, Beijing, China and Peiqing Liu, Faculty of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
Coronavirus 2 (SARS-CoV-2) infection due to severe acute respiratory syndrome can cause acute respiratory misery syndrome, hypercoagulability, high blood pressure and multiorgan dysfunction. In recent months, due to its main infectious strength and pathogenicity, SARS-CoV-2 has gradually spread to more than two hundred countries and regions, leading to more than 500,000 deaths worldwide.
There is a pressing need for effective prevention and remedy (medicines and vaccines) against this highly pathogenic coronavirus. This special factor includes five original study articles, 3 summary articles, and two letters to the editor covering topics similar to the identity easily to be had medications or herbal products as a quick way to provide a clinical remedy in COVID-19 therapy.
Potential healing effects of dipiridamol in critically ill patients with COVID-19 through authors Xiaoyan Liu, Zhe Li, Shuai Liu, Jing Sun and Hai-Bin Luo. Effective antivirals with a safe clinical profile are urgently needed for general prognosis.
In research of a random cohort of 124 patients with COVID-19, the authors found that hypercoagulability is indicated through the maximum grades of D-dimers related to the severity of the disease. known as an anticoagulant agent dipiridamol (DIP) in silico, which suppresses replication of SARS-CoV-2 in vitro.
The crystalline design of the SARS-CoV-2 nucleocapsid protein RNA binding domain shows prospective sites for exclusive drugs through authors Sisi Kang, Mei Yang, Zhongsi Hong, Liping Zhang and Shoudeng Chen. protein remains uncertain.
The authors made a decision on the design of 2. 7″ crystals from the N-terminal RNA binding domain of the SARS-CoV-2 core protein and revealed possible sites unique to the drug target, possibly assisting the consultant in the design of new antiviral agents aimed at SARS. CoV-2.
D3Targets-2019-nCoV: an Internet server waiting for drug targets and for virtual detection of multiple targets and sites as opposed to COVID-19 through authors Yulong Shi, Xinben Zhang, Kaijie Mu, Cheng Peng and Weiliang Zhu. an Internet server founded on the molecular coupling D3Targets-2019-nCoV to drive drug discovery for COVID-19.
The server has two functions; one, expect targets for active compounds, and two, identify difficult compounds through virtual discovery. The Internet server is useful for medical, pharmacologist, and clinical chemists to notice or expand effective SARS-CoV-2 drugs.
Review items
Fight COVID-19 with Chinese and Western classics incorporated in China Liqiang Ni, Lili Chen, Xia Huang, Chouping Han, Hongzhuan Chen.
Bioactive herbal compounds opposed to human coronaviruses: one exam and Yanfang Xian, Juan Zhang, Zhaoxiang Bian, Hua Zhou, Hongxi Xu.
Highly pathogenic coronavirus: vaccine progression highlights Chunting He, Ming Qin, Xun Sun.
Compuscript Ltd
Chen, S. et coll. (2020) Special column: Research on COVID-19 Emerging (target, mechanism and therapeutics). Pharmaceutic Act Sinica B.
News-Medical. net – An AZoNetwork site
Ownership and operation through AZoNetwork, © 2000-2020